MSFrontier

ENSURE-1

A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the
CompletedPhase 3Relapsing MS2021-000028-36

What was tested

Treatment tested

  • Vidofludimus

    Dihydroorotate dehydrogenase inhibitor

What it measured

Main measures

  • Time to first confirmed relapse, as determined by the Independent Neurology Evaluation Committee (INEC), relapse occurred after the start of treatment administration and before the end of the main period (EOMP), censored at a maximum of 72 weeks, Visit 8 (V8)/EOMP

    Relapses

Other measures (1)

  • Key secondary efficacy:

Papers

    Loading reviews and guidelines…

    Related trials

    • TWINS

      Phase 3 · Not yet recruiting

      Still running

    • ENSURE-2

      Phase 3 · Moved to EU CTIS registry

    • AIOLOS

      Recruiting

      Still running

    • FENhance 2

      Phase 3 · Running, not recruiting

      Still running

    • FENhance

      Phase 3 · Running, not recruiting

      Still running

    • TERI-PK

      Phase 4 · Completed

      Result in a paper, not read yet

    History

    1. In scope changed from true to false

    1. Started

      Nov 2021

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error